Related Experiment Video
Updated: Aug 8, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
HCVpred: A web server for predicting the bioactivity of hepatitis C virus NS5B inhibitors
Aijaz Ahmad Malik1, Chuleeporn Phanus-Umporn1, Nalini Schaduangrat1
1Center of Data Mining and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand.
Insights
Researchers developed a predictive model to identify Hepatitis C virus (HCV) NS5B inhibitors. This classification structure-activity relationship (CSAR) model aids in designing more effective anti-HCV drugs.
Area of Science:
- Virology
- Medicinal Chemistry
- Computational Biology
Background:
- Hepatitis C virus (HCV) causes significant liver disease, cirrhosis, and cancer globally.
- NS5B is a crucial viral enzyme and a key therapeutic target for HCV.
- Existing treatments face challenges, necessitating novel drug discovery approaches.
Purpose of the Study:
- To develop a robust classification structure-activity relationship (CSAR) model for identifying anti-HCV NS5B inhibitors.
- To identify key substructures responsible for inhibiting HCV NS5B activity.
- To create a publicly accessible web server for predicting potential HCV NS5B inhibitors.
Main Methods:
- Utilized a dataset of 578 non-redundant compounds with known anti-HCV activity.
- Employed 12 fingerprint descriptors to characterize NS5B inhibitors.
- Constructed predictive models using the random forest algorithm with 100 data splits.
Main Results:
- Achieved a robust modelability index (MODI) of 0.88.
- Demonstrated high predictive performance with accuracy, sensitivity, and specificity exceeding 0.8.
- Identified aromatic rings and alkyl side chains as important for NS5B inhibition.
Conclusions:
- The developed CSAR model is reliable for predicting anti-HCV NS5B activity.
- The findings provide insights into structural features crucial for NS5B inhibition.
- The HCVpred web server facilitates drug design for potent and specific HCV NS5B inhibitors.
Abstract:
Hepatitis C virus (HCV) is one of the major causes of liver disease affecting an estimated 170 million people culminating in 300,000 deaths from cirrhosis or liver cancer. NS5B is one of three potential therapeutic targets against HCV (i.e., the other two being NS3/4A and NS5A) that is central to viral replication. In this study, we developed a classification structure-activity relationship (CSAR) model for identifying substructures giving rise to anti-HCV activities among a set of 578 non-redundant compounds. NS5B inhibitors were described by a set of 12 fingerprint descriptors and predictive models were constructed from 100 independent data splits using the random forest algorithm. The modelability (MODI index) of the data set was determined to be robust with a value of 0.88 exceeding established threshold of 0.65. The predictive performance was deduced by the accuracy, sensitivity, specificity, and Matthews correlation coefficient, which was found to be statistically robust (i.e., the former three parameters afforded values in excess of 0.8 while the latter statistical parameter provided a value >0.7). An in-depth analysis of the top 20 important descriptors revealed that aromatic ring and alkyl side chains are important for NS5B inhibition. Finally, the predictive model is deployed as a publicly accessible HCVpred web server (available at http://codes.bio/hcvpred/) that would allow users to predict the biological activity as being active or inactive against HCV NS5B. Thus, the knowledge and web server presented herein can be used in the design of more potent and specific drugs against the HCV NS5B.
More Related Videos
05:55Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
